 |
|
Acute Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients
Shlomo Matetzky, MD;
Michelle Domingo, BA;
Saibal Kar, MD;
Marko Noc, MD, PhD;
Prediman K. Shah, MD;
Sanjay Kaul, MD;
Eric Daar, MD;
Bojan Cercek, MD, PhD
Arch Intern Med. 2003;163:457-460.
Background Patients infected with human immunodeficiency virus (HIV) are at an increased risk for premature coronary artery disease. However, the clinical outcome of HIV-infected patients who have had an acute myocardial infarction (AMI) is unknown.
Methods We studied 24 consecutive HIV-infected patients admitted because of AMI. During the hospital phase, the patients were examined for recurrent ischemia, congestive heart failure, arrhythmia, and death. Patients were followed up for an average of 15 months after discharge for reinfarction; recurrent angina; the need for any angioplasty, bypass surgery, or target vessel revascularization for restenosis and stent thrombosis; HIV-related complications; and death. For comparison, we included a matched control group of non–HIV-infected patients.
Results The HIV-infected patients with AMI were predominantly male (21 [88%]), 47 ± 9 years of age. Twenty-two (92%) were receiving antiretroviral treatment; 17 (71%), protease inhibitors; and 13 (54%), lipid-lowering therapy. With aggressive therapy, the lipid profile was similar in HIV-infected patients treated with protease inhibitors and those who were not. Twenty-one (88%) of 24 patients underwent immediate angiography and 20 (83%) had angioplasty or bypass surgery. The HIV-infected patients with AMI had a benign in-hospital course, with no deaths or reinfarction. The admission characteristics, treatment strategy, and in-hospital outcome were similar in the matched uninfected patients with AMI. After discharge, HIV-infected patients had a higher incidence of reinfarction (4/20 [20%] vs 2/45 [4%]; P = .07), and 6 (43%) of 14 HIV-infected patients who had successful percutaneous coronary intervention and were available for follow-up required target vessel revascularization compared with 4 (11%) of 38 uninfected patients who had successful percutaneous coronary intervention and were available for follow-up (P = .02).
Conclusions Patients infected with HIV sustain AMI at a young age and have a benign in-hospital course. Although HIV-infected patients have a higher incidence of postdischarge ischemic events, restenosis, and stent thrombosis, the intermediate-term mortality is low.
From the Divisions of Cardiology (Drs Matetzky, Kar, Noc, Shah, Kaul, and Cercek and Ms Domingo) and Infectious Diseases (Dr Daar), Cedars-Sinai Medical Center, Los Angeles, Calif.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis.
Boccara et al.
Heart 2006;92:543-544.
FULL TEXT
What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus Infection
Hsue and Waters
Circulation 2005;112:3947-3957.
ABSTRACT
| FULL TEXT
HIV-1 Accessory Protein Vpr Inhibits the Effect of Insulin on the Foxo Subfamily of Forkhead Transcription Factors by Interfering With Their Binding to 14-3-3 Proteins: Potential Clinical Implications Regarding the Insulin Resistance of HIV-1-Infected Patients
Kino et al.
Diabetes 2005;54:23-31.
ABSTRACT
| FULL TEXT
|
